Sep 12, 2022

The National Hemophilia Foundation (NHF) and Medscape are pleased to announce the first live activity in a Virtual Grand Round Series on “Gene Therapy for Patients with Hemophilia.”

The program, presented through a collaboration between the NHF and Medscape, was designed to foster expert discussion on new insights based on the latest data from phase 3 gene therapy trials. The opening activity, which will be held on Tuesday, October 4, 2022, from 12pm-1pm ET, is intended for hematologists, nurses/nurse practitioners, pediatricians, primary care physicians, and physician assistants.

Participants who complete the activity will:

Have increased knowledge regarding the

  • Clinical trial data on gene therapy for hemophilia

  • Implications of gene therapy in the management of hemophilia

Demonstrate greater confidence in their ability to

  • Implement gene therapy in an interprofessional care team environment

There is no cost associated with this activity. Visit the event homepage for more information, including accreditation details, and to register.

This program is supported by independent educational grant from CSL Behring and Spark Therapeutics.